SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DNLI

Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · USD
Healthcare · Biotechnology
$18.45+$0.25 (+1.37%)
 
Market cap
$2.96B
Insider Score
Analyst consensus
Market Cap$2.96B+7.5%
Revenue (ttm)$21.38M
Net Income-$314.42M
EPS-$1.72
Shares Out160.29M
PE Ration/a
Forward PE-8.17
Dividendn/a
Ex-Dividend Daten/a
Volume2,632,241
Open$17.95
Previous Close$18.20
Day's Range$17.92 - $18.85
52-Week Range$15.34 - $27.30
Beta1.08
AnalystsStrong Buy
Price Target$35.82(+94.17%)
Earnings DateNov 3, 2026

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Address
161 Oyster Point Boulevard, South San Francisco, CA, 94080, United States
Market Cap
2.96 billion
Employees
503
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.30M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $34.50 (+87.5%)

4 firms rating DNLI in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+1.37%
5 Days
-1.55%
1 Month
-1.13%
6 Months
-1.02%
1 Year
+7.52%

$DNLI stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DNLI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DNLI's directors and management

Net Shares Purchased by Insiders−60k−30k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DNLI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

DNLI Revenue by Segment

$196.88MTotal
Gain on sale of priority review voucher, net$194.00M98.54%
Segment interest and other income, net$2.88M1.46%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New DNLI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DNLI from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from DNLI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Wells Fargo initiated coverage with Overweight rating and $35 price target; pipeline milestones nearing with expanded Hunter Disease patient targeting represent concrete positive catalysts.

Recent Insider Activity

Buys
0
Sells
7
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-48.0 since Aug 21
0255075100Aug 21 — Insider Score 48.0Aug 22 — Insider Score 48.0Aug 23 — Insider Score 48.0Aug 24 — Insider Score 48.0Aug 25 — Insider Score 47.0Aug 26 — Insider Score 47.0Aug 27 — Insider Score 47.0Aug 28 — Insider Score 47.0Aug 29 — Insider Score 47.0Aug 30 — Insider Score 47.0Aug 31 — Insider Score 47.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 29.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MNTLTema Neuroscience And Mental Health ETF1.98%
SBIOALPS Medical Breakthroughs ETF1.98%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF1.72%
BBPVirtus Biotech ETF1.17%
TDNAT. Rowe Price Biotech ETF1.08%
BGUSBaillie Gifford U.S. Equity Growth ETF0.61%
XBIState Street SPDR S&P Biotech ETF0.58%
TSEET. Rowe Price Small Cap ETF0.42%
NIXTResearch Affiliates Deletions ETF0.42%
TCAFT. Rowe Capital Appreciation Equity ETF0.32%
LNGRGlobal X Aging Population ETF0.30%
TMIDT. Rowe Price Mid Cap Equity Research ETF0.26%

Weight is the stock’s share of each fund’s holdings.